Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: Long-term patient survival and mechanism of function

V Schirrmacher, P Fournier, P Schlag - Expert review of vaccines, 2014 - Taylor & Francis
V Schirrmacher, P Fournier, P Schlag
Expert review of vaccines, 2014Taylor & Francis
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide.
Surgery remains the primary curative treatment but nearly 50% of patients relapse as
consequence of micrometastatic or minimal residual disease (MRD) at the time of surgery.
Spontaneous T-cell-mediated immune responses to CRC tumor-associated antigens (TAAs)
in tumor-draining lymph nodes and in the bone marrow (BM) lead to infiltration of the tumors
by lymphocytes. Certain types of such tumor-infiltrating lymphocytes (TILs) have a positive …
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. Surgery remains the primary curative treatment but nearly 50% of patients relapse as consequence of micrometastatic or minimal residual disease (MRD) at the time of surgery. Spontaneous T-cell-mediated immune responses to CRC tumor-associated antigens (TAAs) in tumor-draining lymph nodes and in the bone marrow (BM) lead to infiltration of the tumors by lymphocytes. Certain types of such tumor-infiltrating lymphocytes (TILs) have a positive and others a negative impact on the patients' prognosis. This review focuses on advances in CRC active-specific immunotherapy (ASI), in particular on results from randomized controlled clinical studies employing therapeutic autologous tumor cell vaccines. The observed improvement of long-term survival is explained by activation and mobilization of a pre-existing repertoire of tumor-reactive memory T cells which, according to recent discoveries, reside in distinct niches of patients' bone marrow in neighborhood with hematopoietic (HSC) and mesenchymal (MSC) stem cells. Interestingly, memory T cells also contain a subset of stem memory T cells (SMTs) in addition to effector (EMTs) and central memory T cells (CMTs). The mechanism of function of a therapeutic vaccine in a chronic disease is distinct from that of prophylactic vaccines which have to generate de novo protective immune responses. The advantage of autologous vaccines for mobilization of a broad and highly individual repertoire of memory T cells will be discussed.
Taylor & Francis Online